Trends and Outcomes in Cardiac Arrest Among Heart Failure Admissions
- PMID: 36889986
- DOI: 10.1016/j.amjcard.2023.01.012
Trends and Outcomes in Cardiac Arrest Among Heart Failure Admissions
Abstract
There is limited large, national data investigating the prevalence, characteristics, and outcomes of cardiac arrest (CA) in patients hospitalized for heart failure (HF). The goal of this study was to examine the characteristics, trends, and outcomes of HF hospitalizations complicated by in-hospital CA. We used the National Inpatient Sample to identify all primary HF admissions from 2016 to 2019. Cohorts were built based on the presence of a codiagnosis of CA. Diagnoses were identified using International Classification of Diseases, Tenth Revision, Clinical Modification codes. Associations with CA were then analyzed using multivariate logistic regression. We identified a total of 4,905,564 HF admissions, 56,170 (1.1%) of which had CA. Hospitalizations complicated by CA were significantly more likely to be male, to have coronary artery disease, renal disease, and less likely to be White (p <0.001, all). Age <65 (odds ratio [OR] 1.18, p <0.001), renal disease (OR 2.41, p <0.001), and coronary artery disease (OR 1.26, p <0.001) had higher odds of CA while female gender (OR 0.84, confidence interval [CI] 0.83 to 0.86, p <0.001) or HFpEF (OR 0.49, CI 0.48 to 0.50, p <0.001) had lower odds of CA. Patients with CA had higher inpatient mortality (CA 54.2% vs no CA 2.1%, p <0.001), which persisted after multivariate adjustment (OR 64.8, CI 63.5 to 66.0, p <0.001). CA occurs in >1 in 1,000 HF hospitalizations and remains a prominent and serious event associated with a high mortality. Further research is needed to examine long-term outcomes and mechanical circulatory support utilization with more granularity in HF patients with in-hospital CA.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures Dr. Fudim was supported by the National Heart, Lung, and Blood Institute (K23HL151744), the American Heart Association (20IPA35310955), Mario Family Award, Duke Chair's Award, Translating Duke Health Award, Bayer, Bodyport, and BTG Specialty Pharmaceuticals. He receives consulting fees from AxonTherapies, Bodyport, Boston Scientific, CVRx, Daxor, Edwards Lifesciences, Fire1, Inovise, NXT Biomedical, Viscardia, Zoll. Dr. Ahmad is a consultant for Amgen, cytokinetics, Relypsa, and Novartis. The remaining authors have no conflicts of interest to declare.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
